TABLE 1.
Associations between GIST FGL2 expression and eight clinicopathological factors in the western Sweden series
| Factor | GIST FGL2 expression | p | |
|---|---|---|---|
| Negative N = 33 n (%) | Positive N = 120 n (%) | ||
| Gender | |||
| Male | 17 (24.3) | 53 (75.7) | |
| Female | 16 (19.3) | 67 (80.7) | 0.453 |
| Site | |||
| Gastric | 16 (19.3) | 67 (80.7) | |
| Nongastric | 17 (24.3) | 53 (75.7) | 0.453 |
| NIH risk stratification | |||
| Low/intermediate | 16 (15.5) | 87 (84.5) | |
| High | 17 (34.0) | 33 (66.0) | 0.009 |
| Histological type | |||
| Spindle cell | 18 (16.5) | 91 (83.5) | |
| Other | 13 (33.3) | 26 (66.7) | 0.027 |
| N.A. | 2 | 3 | |
| Tumour necrosis | |||
| Absent | 11 (14.7) | 64 (85.3) | |
| Present | 12 (33.3) | 24 (66.7) | 0.023 |
| N.A. | 10 | 32 | |
| Mitotic count (per 50 HPFs) | |||
| 0–5 | 19 (16.2) | 98 (83.8) | |
| >5 | 12 (38.7) | 19 (61.3) | 0.006 |
| N.A. | 2 | 3 | |
| Median age, years (range) | 68 (46–83) | 69 (30–92) | 0.619 |
| Median tumour size, cm (range) | 9.7 (1.0–30.0) | 6.7 (0.5–33.0) | 0.029 |
Abbreviations: HPF, high‐power field of the microscope; N.A., not available; NIH, the National Institutes of Health.